Bonus Biogroup (BONS) - Net Assets

Latest as of June 2025: ILA-1.68 Million ILA ≈ $-4.49K USD

Based on the latest financial reports, Bonus Biogroup (BONS) has net assets worth ILA-1.68 Million ILA (≈ $-4.49K USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA17.33 Million ≈ $46.46K USD) and total liabilities (ILA19.00 Million ≈ $50.95K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Bonus Biogroup's assets to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	ILA-1.68 Million
% of Total Assets	-9.67%
Annual Growth Rate	-3.28%
5-Year Change	-77.33%
10-Year Change	N/A
Growth Volatility	134.58

Bonus Biogroup - Net Assets Trend (2008–2024)

This chart illustrates how Bonus Biogroup's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Bonus Biogroup for the complete picture of this company's asset base.

Annual Net Assets for Bonus Biogroup (2008–2024)

The table below shows the annual net assets of Bonus Biogroup from 2008 to 2024. For live valuation and market cap data, see market cap of Bonus Biogroup.

Year	Net Assets	Change
2024-12-31	ILA6.96 Million ≈ $18.65K	-76.26%
2023-12-31	ILA29.30 Million ≈ $78.57K	-48.03%
2022-12-31	ILA56.39 Million ≈ $151.18K	-33.21%
2021-12-31	ILA84.43 Million ≈ $226.35K	+175.16%
2020-12-31	ILA30.68 Million ≈ $82.26K	+323.63%
2019-12-31	ILA-13.72 Million ≈ $-36.79K	-331.89%
2018-12-31	ILA-3.18 Million ≈ $-8.52K	+50.23%
2017-12-31	ILA-6.38 Million ≈ $-17.12K	+13.30%
2016-12-31	ILA-7.36 Million ≈ $-19.74K	-430.09%
2015-12-31	ILA-1.39 Million ≈ $-3.72K	-329.97%
2014-12-31	ILA604.00K ≈ $1.62K	-90.63%
2013-12-31	ILA6.45 Million ≈ $17.28K	-13.74%
2012-12-31	ILA7.47 Million ≈ $20.03K	+948.13%
2011-12-31	ILA-881.00K ≈ $-2.36K	+97.69%
2010-12-31	ILA-38.19 Million ≈ $-102.39K	-307.07%
2009-12-31	ILA-9.38 Million ≈ $-25.15K	-179.08%
2008-12-31	ILA11.86 Million ≈ $31.81K	--

Equity Component Analysis

This analysis shows how different components contribute to Bonus Biogroup's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 31533000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Common Stock	ILA303.31 Million	4359.85%
Other Comprehensive Income	ILA41.25 Million	592.87%
Other Components	ILA1.00	0.00%
Total Equity	ILA6.96 Million	100.00%

Bonus Biogroup Competitors by Market Cap

The table below lists competitors of Bonus Biogroup ranked by their market capitalization.

Company	Market Cap
Marvipol S.A. WAR:MVP	$130.11 Million
ARRAIL GROUP LTD. F:I1D	$130.12 Million
John Hancock Income Securities Closed Fund NYSE:JHS	$130.21 Million
AB Klaipedos nafta F:XIC	$130.27 Million
Gevelot PA:ALGEV	$129.92 Million
Bancroft Fund Limited NYSE MKT:BCV	$129.90 Million
Amotech Co. Ltd KQ:052710	$129.86 Million
Prosafe SE OL:PRS	$129.84 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Bonus Biogroup's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 29,305,000 to 6,957,000, a change of -22,348,000 (-76.3%).
Net loss of 27,826,000 reduced equity.
New share issuances of 3,850,000 increased equity.
Other comprehensive income increased equity by 41,209,580.
Other factors decreased equity by 39,581,580.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	ILA-27.83 Million	-399.97%
Share Issuances	ILA3.85 Million	+55.34%
Other Comprehensive Income	ILA41.21 Million	+592.35%
Other Changes	ILA-39.58 Million	-568.95%
Total Change	ILA-	-76.26%

Book Value vs Market Value Analysis

This analysis compares Bonus Biogroup's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 6966.92x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has increased from 1178.57x to 6966.92x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2012-12-31	ILA0.04	ILA41.50	x
2013-12-31	ILA0.04	ILA41.50	x
2014-12-31	ILA0.00	ILA41.50	x
2015-12-31	ILA-0.01	ILA41.50	x
2016-12-31	ILA-0.03	ILA41.50	x
2017-12-31	ILA-0.01	ILA41.50	x
2018-12-31	ILA0.00	ILA41.50	x
2019-12-31	ILA-0.02	ILA41.50	x
2020-12-31	ILA0.03	ILA41.50	x
2021-12-31	ILA0.15	ILA41.50	x
2022-12-31	ILA0.09	ILA41.50	x
2023-12-31	ILA0.03	ILA41.50	x
2024-12-31	ILA0.01	ILA41.50	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Bonus Biogroup utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -399.97%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 0.00%
• Asset Turnover: 0.00x
• Equity Multiplier: 3.36x
Recent ROE (-399.97%) is below the historical average (-177.53%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2008	1.15%	0.24%	1.10x	4.28x	ILA-1.05 Million
2009	0.00%	-23.22%	1.89x	0.00x	ILA-20.74 Million
2010	0.00%	-22.96%	5.29x	0.00x	ILA-3.55 Million
2011	-28.29%	0.00%	0.00x	0.00x	ILA-1.40 Million
2012	-240.54%	0.00%	0.00x	1.18x	ILA-18.72 Million
2013	-150.52%	0.00%	0.00x	1.27x	ILA-10.35 Million
2014	-1855.46%	0.00%	0.00x	7.49x	ILA-11.27 Million
2015	0.00%	0.00%	0.00x	0.00x	ILA-13.32 Million
2016	0.00%	0.00%	0.00x	0.00x	ILA-15.31 Million
2017	0.00%	0.00%	0.00x	0.00x	ILA-19.56 Million
2018	0.00%	0.00%	0.00x	0.00x	ILA-18.42 Million
2019	0.00%	0.00%	0.00x	0.00x	ILA-20.87 Million
2020	-71.77%	0.00%	0.00x	1.68x	ILA-25.09 Million
2021	-106.69%	0.00%	0.00x	1.24x	ILA-98.52 Million
2022	-68.64%	0.00%	0.00x	1.32x	ILA-44.34 Million
2023	-97.35%	0.00%	0.00x	1.53x	ILA-31.46 Million
2024	-399.97%	0.00%	0.00x	3.36x	ILA-28.52 Million

Industry Comparison

This section compares Bonus Biogroup's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $45,690,709
Average return on equity (ROE) among peers: -39.10%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Bonus Biogroup (BONS)	ILA-1.68 Million	1.15%	N/A	$129.94 Million
BioLine RX Ltd (BLRX)	$-1.25 Million	0.00%	0.00x	$11.90 Million
BioLight Life Sciences Ltd (BOLT)	$68.15 Million	-18.48%	0.10x	$6.40 Million
Can Fite Biopharma Ltd (CANF)	$3.29 Million	-203.55%	0.49x	$5.73 Million
Clal Biotechnology Industries Ltd (CBI)	$144.90 Million	-42.61%	0.26x	$14.30 Million
Compugen (CGEN)	$12.79 Million	-63.57%	0.21x	$209.46 Million
DNA Biomed Solns (DNA)	$79.19 Million	-1.49%	0.02x	$36.65 Million
Enlivex Therapeutics Ltd (ENLV)	$85.04 Million	-17.01%	0.12x	$519.31K
Evogene (EVGN)	$48.26 Million	-5.23%	0.34x	$5.60 Million
Kadimastem Ltd (KDST)	$-29.15 Million	0.00%	0.00x	$22.18 Million

About Bonus Biogroup

TA:BONS Israel Biotechnology

Market Cap

$129.94 Million

ILA48.47 Billion ILA

Market Cap Rank

#18205 Global

#234 in Israel

Share Price

ILA41.50

Change (1 day)

+0.48%

52-Week Range

ILA19.50 - ILA58.50

All Time High

ILA171.00